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Infectious clone methodology is a valuable tool of modern experimental virology. However, its use is often constrained by
the instability of infectious clone constructs during propagation in E. coli. To circumvent this problem, we have devised a
strategy that could be suitable for design of (1)RNA virus molecular clones in general. An infectious clone is assembled as
“infectious DNA,” and expression of problem regions present in the viral cDNA is prevented during propagation in E. coli by
insertion of short introns. To demonstrate the feasibility of this approach, a highly unstable Japanese encephalitis flavivirus
infectious clone has been successfully converted into a remarkably stable infectious DNA construct with the specific
infectivity of 106 pfu/mg in cell culture. The proposed strategy may be useful in the design of self-amplifying gene therapy
vectors and development of new immunization methodologies, and could facilitate creation of molecular repositories of
existing viral vaccines. © 2001 Academic PressKey Words: (1)RNA virus; flavivirus; Japanese encephalitis; infectious clone; instability; infectious DNA; transcription;
intron.INTRODUCTION
Infectious clone methodology, which allows direct ma-
nipulation of viral genomes, is a highly valuable tool of
modern experimental virology. However, its use and
practical importance are often limited due to instability of
viral genome-encoding plasmids (viral infectious clones)
during propagation in E. coli. The problem is especially
manifested in (1)RNA viruses. As a consequence, infec-
tious clones for some viruses are either impossible to
assemble, or once assembled, are very difficult to main-
tain in E. coli due to their predisposition to spontaneous
rearrangements and/or to acquisition of stabilizing mu-
tations. One plausible explanation is that such instability
results from unanticipated expression of viral cDNA en-
coding products toxic to the bacterial host. While stable
infectious clones for some viruses have been reported
(Boyer and Haenni, 1994; Khromykh and Westaway, 1994;
Meyers et al., 1996; Geigenmuller et al., 1997), similar
constructs for other viruses exhibit acceptable stability
only after assembly in low copy number vectors (Gritsun
and Gould, 1998; Gualano et al., 1998; Mendez et al.,
1998; Hurrelbrink et al., 1999; Almazan et al., 2000). For
certain viruses more sophisticated procedures have
been used for assembly of infectious clone cDNA tem-
plates in order to circumvent the instability problem,
such as ligation in vitro (Sumiyoshi et al., 1992; Kapoor et
al., 1995), long high-fidelity PCR (Campbell and Pletnev,1 To whom reprint requests should be addressed. Fax: 804/243-6169.
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2722000), or a combination of both (Herold et al., 1998). Use
of nonbacterial cloning systems (Polo et al., 1997) has
been reported as well.
Due to the infectious nature of (1)RNA virus genomes,
delivery of (1)RNA transcribed from corresponding viral
genome cDNA templates into susceptible cells initiates
the viral replication cycle. According to the established
practice, (1)RNA viruses are recovered from infectious
clones after transfection of synthetic RNA into suscepti-
ble cells. This approach also has been proven success-
ful in vivo using synthetic RNA representing genomes of
infectious viruses (Gritsun and Gould, 1995; Mandl et al.,
1998), as well as recombinant alphavirus replicons (Zhou
et al., 1994; Fleeton et al., 1999; Leitner et al., 1999).
Although as little as 1 ng of infectious virus RNA (Mandl
et al., 1998) or 100 ng of recombinant replicon RNA (Ying
et al., 1999) elicited antigen-specific responses upon
inoculation in mice, the vulnerability of RNA to degrada-
tion undermines the practical importance of this ap-
proach. Perhaps for this reason, a DNA/RNA layered
approach (Herweijer et al., 1995; Dubensky et al., 1996)
has been developed, in which genomic RNA is made in
situ by nuclear transcription of viral genome cDNA tem-
plates from eukaryotic promoters in cells transfected
with correspondingly engineered plasmid DNA, thus
leading to initiation of viral RNA replication. However,
despite many advantages of the DNA-based approach,
only a few examples of infectious DNA for animal viruses
have been reported (Semler et al., 1984; Herweijer et al.,
1995; Dubensky et al., 1996; Beard et al., 1999). This
approach has found a broader use in the field of plant
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273DESIGN OF (1)RNA VIRUS INFECTIOUS CLONESviruses (reviewed in Boyer and Haenni, 1994). The insta-
bility problem likely represents a major obstacle imped-
ing development of infectious DNA constructs for other
(1)RNA viruses. Indeed, if unanticipated expression of
viral genome segments in E. coli serves as a chief factor
leading to destabilization of plasmids, eukaryotic pro-
moters will only exacerbate its detrimental effects. Sub-
stantial transcriptional activity of both viral and cellular
eukaryotic promoters has been demonstrated in E. coli
(Davis and Huang, 1988; Antonucci et al., 1989).
We have devised a new strategy, which circumvents
the problem of infectious clone instability in E. coli. The
proposed strategy is based on the differences in RNA
processing between prokaryotes and eukaryotes and
allows one to exploit benefits of the infectious DNA
methodology. Japanese encephalitis (JE) virus belongs to
the Flaviviridae family of (1)RNA viruses, which also
includes yellow fever (YF), West Nile, tick borne enceph-
alitis, dengue, and hepatitis C viruses. Flaviviruses, in
particular JE (Sumiyoshi et al., 1992) and YF (Rice et al.,
1989), represent the most striking examples of highly
unstable infectious clones, which have been composed
by in vitro ligation. By creating a remarkably stable con-
struct containing the JE genome under control of the
strong cytomegalovirus promoter (CMVp/e), we demon-
strate the feasibility of our approach for the design of
stable infectious clones. Direct transfection of infectious
JE DNA constructs into BHK cells leads to prompt initi-
ation of productive virus replication, greatly simplifying
virus recovery. We believe that the proposed scheme
may find a broad use in the design of stable infectious
clones of other (1)RNA viruses.
RESULTS
Two original JE plasmids, pM343 and pH756, encoding
roughly two halves of the JE virus genome have been
described (Sumiyoshi et al., 1992). The former plasmid
was unstable in E. coli, and exhibited a high propensity
or rearrangements. Interestingly, spontaneous “large
olony size” mutants of pM343, isolated by us and re-
orted earlier (Sumiyoshi et al., 1992), often contained
nonsense mutations at the end of E gene. Using repaired
pM343 (designated pT7JE59) and a derivative of pH756
(designated pJE39/Asp), the full-length JE clone (desig-
nated pT7JE/Asp) has been assembled in pBR322. Syn-
thetic RNA made with T7 RNA polymerase was infec-
tious, and the recovered virus was similar to the parent
JaOArS982 strain by several criteria (V. Yamshchikov,
unpublished). To our knowledge, this is the first success-
ful attempt to assemble a full infectious clone of JE virus
in a bacterial plasmid; a complete description of this
study will be reported elsewhere. In this report, the virus
recovered from the pT7JE/Asp clone will be referred to
as the parent virus. Compared to pT7JE59, pT7JE/Asp
displayed much higher predisposition to rearrangementsand very poor growth characteristics upon propagation
in E. coli.
Design of stable JE infectious DNA
Initial attempts to assemble the JE 59-half genome
cassette downstream from CMVp/e failed because only
plasmids with extensive deletions were recovered. Pre-
sumably, the instability of the plasmids was caused by
CMVp/e, since substantial transcriptional activity in E.
coli has been reported for this and other eukaryotic
promoters (Davis and Huang, 1988; Antonucci et al.,
1989). Earlier we noticed that nonsense mutations up-
stream from hydrophobic domains present at the end of
E and beginning of NS1 (Fig. 1a) often resulted in stabi-
lization of the pT7JE59 plasmid. We intentionally intro-
duced stop codons upstream from this region as part of
an intron. A site for Ecl136 II, GAG/CTC, located at pos.
2215 upstream from the problem region, was used for
insertion of a 132-bp chimeric intron producing sequence
59 . . .GAGGT. . .AGCTC. . .39 (an abbreviated sequence of
the intron is in bold). Precise excision of the intron due to
splicing in mammalian cells would restore the original
restriction site, thus providing a simple means to monitor
processing of transcripts. Although the resulting
pT7JE59(i2217) plasmid appeared stable, replacement of
the T7 promoter with CMVp/e caused substantial desta-
bilization of the construct since the majority of recovered
plasmids contained various rearrangements. One of
pCMVp/eJE59(i2217) plasmids appeared to contain the JE
fragment of the correct length; however, transfection of
this plasmid into BHK cells did not result in JE-specific
cell fluorescence (Fig. 3, panel a-1). A 5-nt frameshift
deletion was found upstream from the region encoding
the prM signal sequence, suggesting that expression of
this genome region may have caused destabilization. To
alleviate this problem, a second copy of the same intron
was inserted in the Ecl136 II site, created at pos. 354
FIG. 1. Recombinant constructs used in this study. (a) Organization of
the JE genome and abbreviated designations of viral proteins are
presented according to (Rice, 1996). KpnI is an isoshizomer of Asp718.
ertical bars mark gene boundaries, and thicker vertical bars designate
ydrophobic protein domains. Pos. 356 and 2217 of intron (i) insertion
re indicated. (b) Arrangement of the CMVp/e transcription start (arrow)
nd beginning of the JE genome (in bold). The TATA element is boxed
(Thomsen et al., 1984).upstream from this genome region (Fig. 1a). The result-
ing pCMVp/eJE59(i356i2217) construct had excellent sta-
274 YAMSHCHIKOV, MISHIN, AND COMINELLIbility and growth characteristics, despite the presence of
the direct repeat. Cells transfected with this plasmid
showed bright JE-specific fluorescence (Fig. 3, panel
a-2), indicating efficient formation of JE antigens. Inter-
estingly, a plasmid without i2217 appeared much less
stable. However, we isolated unperturbed pCMVp/
eJE59(i356), which also produced bright JE-specific cell
fluorescence upon transfection (Fig. 3, panel a-3). The
CMVp/eJE59(i356i2217) and CMVp/eJE59(i356) cassettes
were joined with the JE39/Asp fragment representing the
second half of the JE genome in order to assemble full
genome JE cDNA under transcriptional control of
CMVp/e. The plasmid containing two introns produced
uniformly round, large colonies upon transformation in E.
coli. In contrast, the single intron plasmid always pro-
duced heterogeneous colonies, indicating a high ten-
dency for rearrangements (Polo et al., 1997). The JE insert
in pCMVp/eJE(i356i2217) was completely sequenced,
and no changes were found when compared to the
original pT7JE/Asp construct. No changes were found
when the plasmid was sequenced again after six se-
quential transformation–isolation cycles in E. coli HB101,
thus attesting to the excellent stability of the construct. In
order to ensure defined termination and polyadenylation
of in vivo transcripts, the bovine growth hormone tran-
scription termination and polyadenylation signal (BGHTT)
was inserted at the 39-end of the JE genome in both
constructs, resulting in pCMVp/eJE(i356i2217)BGHTT and
pCMVp/eJE(i356)BGHTT (Figs. 1a and 1b).
Thus, by suppressing deleterious expression of viral
genome regions in E. coli at the level of translation, we
have converted the highly unstable viral infectious clone
into a remarkably stable construct controlled by a eu-
karyotic promoter. Based on indirect immunofluores-
cence of the half-genome constructs, intron sequences
were recognized in eukaryotic cells and appeared to be
precisely removed from the primary transcripts, resulting
in synthesis of viral antigens.
Characterization of in vivo transcripts
Initiation and termination of in vivo transcripts was
analyzed using a model plasmid pCMVp/e59D39BGHTT.
Gel-purified products of nested PCR obtained in RLM-
RACE assays, as described under Materials and Meth-
ods, were sequenced directly with JE-specific primers.
The 59-end sequence of the JE genome (GenBank No.
M18370) was clearly readable up to its very first nucle-
otide, with the sequence ambiguity commencing after-
ward. This indicated that the majority of transcripts in-
cluded the complete 59-untranslated region, and certain
infidelity of transcription initiation resulted in addition of
only a few nucleotides upstream from the beginning of JE
genome. We did not study this in more detail.To determine if transcription termination occurs ac-
cording to the designed scheme, total RNA from cellstransfected with pCMVp/e59D39BGHTT was analyzed in
an adapted 39-end assay (Salles et al., 1999), as de-
scribed under Materials and Methods. Isolated RT-PCR
fragment contained the complete 39-terminus of the JE
genome (GenBank No. M18370), followed by the 59-
proximal 137 nt of BGHTT up to the polyadenylation site
(Woychik et al., 1982) and including a poly(A)tail, thus
confirming that transcription termination and polyadenyl-
ation were directed by BGHTT as expected. The length of
the poly(A) tail has not been determined.
Splicing of primary transcripts was studied in cells
transiently transfected with the half-genome cassettes
pCMVp/eJE59(i2217) and pCMVp/eJE59(i356i2217). Using
primers flanking the i2217 site of intron insertion, a frag-
ment was detected by RT-PCR analysis of total RNA
isolated from cells transfected with pCMVp/eJE59(i2217)
(Fig. 2a, lane 3), which was of the same size as the
364-bp fragment amplified from the original pT7JE59
(lane 2). The 496-bp intron-containing fragment (lane 1)
was not detected. The presence of the Ecl136 II site (lane
4) evidenced precise removal of the intron and hence
restoration of the ORF. This conclusion was further con-
firmed by sequence analysis of this fragment. Total
RNA isolated from cells transfected with pCMVp/
eJE59(i356i2217) was also analyzed by RT-PCR with prim-
ers flanking the i356 site of the intron insertion. Again, an
amplification product originating from spliced tran-
scripts, i.e., 943 bp rather than 1075 bp long, was de-
tected (Fig. 2b, lane 3). The fragment also contained the
FIG. 2. Splicing of the primary in vivo transcripts. (a) Total RNA
isolated from BHK cells 24 h after transfection with pCMVp/eJE59(i2217)
was assayed by RT-PCR using the primer pair flanking pos. 2217 of
intron insertion. Fragments with and without the intron were amplified
from pCMVp/eJE59(i2217) and pT7JE59, respectively, using the same
primers. Lane 1, the fragment with the intron in pos. 2217; lane 2, the
fragment without the intron; lane 3, RT-PCR product from total RNA;
lane 4, RT-PCR product digested with Ecl136 II. (b) Total RNA isolated
from BHK cells 24 h after transfection with pCMVp/eJE59(i356i2217) was
assayed by RT-PCR using the primer pairs flanking the i356 and both
i356 and i2217 sites of intron insertion. Fragments with and without the
intron(s) were amplified from pCMVp/eJE59(i356i2217) and pT7JE59,
respectively, using the same primer pairs as in respective RT-PCR
assays. Lane 1, the fragment with the intron in pos. 356; lane 2, the
fragment without the intron; lane 3, RT-PCR product from total RNA with
primers flanking pos. 356; lane 4, the RT-PCR product present in lane 3
after digestion with Ecl136 II; lane 5, RT-PCR product of total RNA with
primers flanking both pos. 356 and 2217; lane 6, the fragment without
the introns; lane 7, the fragment containing both introns.Ecl136 II site (lane 4), evidencing precise excision of the
intron and ORF restoration. We confirmed this by com-
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275DESIGN OF (1)RNA VIRUS INFECTIOUS CLONESplete sequencing of the fragment. We were not able to
detect alternative splicing for this construct (i.e., the
donor site of the first intron to the acceptor site of the
second intron resulting in deletion of a 1860-bp fragment
of the JE genome) since a 2330-bp fragment rather than
a 470-bp fragment was identified with primers flanking
the i356 and i2217 sites (lane 5). This is consistent with
the linear scanning model of splice site selection (Lang
and Spritz, 1983; Smith et al., 1989). This fragment was
also completely sequenced.
Thus, defined termination of transcription, polyadenyl-
ation, and correct splicing of transcripts with restoration
of the viral ORF have been observed upon transfection of
the model constructs into eukaryotic cells. Although tran-
scripts were heterogeneous at their 59-ends, some cor-
rectly initiated transcripts that could launch a productive
infectious cycle were apparently present.
Transfection of infectious DNA initiates the viral
replication cycle
Synthesis of JE-specific antigens in transfected cells
was monitored by indirect immunofluorescence, which
provided a functional test for ORF integrity. Proper folding
of flavivirus structural proteins depends on activity of the
viral protease (Mason et al., 1991; Yamshchikov and
Compans, 1993). Since the protease domain of NS3 was
encoded at the end of the JE59 cassettes, efficient for-
mation of JE antigens would attest to both correct splic-
ing and the presence of the uninterrupted ORF through
the entire transcript. Indeed, cells transfected with
pCMVp/eJE59(i356i2217) were highly antigen-positive
(Fig. 3, panel a-2). In contrast, no JE-specific fluores-
cence was detected in cells transfected with the above-
described frameshift mutant of pCMVp/eJE59(i2217) (Fig.
3, panel a-1), despite correct splicing of the transcript.
Transfection with pCMVp/eJE(i356i2217)BGHTT also
FIG. 3. Detection of viral proteins in transfected cells by indirect
mmunofluorescence. Transfected BHK cells were fixed at indicated
ime points (hours post-transfection, hpt) in cold acetic acid–methanol
nd reacted with JE AF, following by goat anti-mouse IgG conjugated to
luorescein. (a) Cells transfected with 1, the deletion variant of pCMVp/
JE59(i2217); 2, pCMVp/eJE59(i356i2217); 3, pCMVp/eJE59(i356); and 4,
BR322 were assayed at 24 hpt. (b) Cells transfected with pCMVp/
JE(i356i2217)BGHTT were assayed at 1, 24 hpt; 2, 48 hpt; 3, 72 hpt; and
, 96 hpt.produced intensely fluorescent cells, which rapidly in-
creased in number with time until all cells in the mono-layer became JE-positive (Fig. 3, panel b). This indicated
formation of infectious virus and spread of infection. To
confirm the immunofluorescence data, we investigated
synthesis of JE-specific proteins and RNA in cells trans-
fected with pCMVp/eJE(i356i2217)BGHTT. The same sets
of JE-specific proteins were immunoprecipitated with JE-
specific antiserum from both lysates of transfected cells
and cells infected with the parent virus (Fig. 4a). Synthe-
sis of viral proteins was readily detectable at 5 h after
DNA–cell contact, and increased progressively during
incubation. Accordingly, increasing amounts of JE-spe-
cific RNA were detected by ribonuclease protection as-
say using a probe complementary to the first 175 nt of the
JE genome RNA (Fig. 4b).
Finally, we have isolated infectious virus from cells
transfected with plasmids containing full JE genome
cDNA cassettes. Figure 5a shows virus accumulation in
the media sampled at various time points after transfec-
tion with these DNA. In parallel experiments, all con-
structs produced virus with similar accumulation rates.
FIG. 4. Synthesis of JE-specific proteins and RNA in pCMVp/
eJE(i356i2217)BGHTT-transfected cells. (a) Cell lysates prepared at
indicated time points (hours) after cell–DNA contact were immunopre-
cipitated with JE HMAF and protein A–agarose conjugate. Lane JE,
cells at 72 h after infection with the parent virus. (b) Total RNA isolated
from cells at indicated time points (hours) after transfection was tested
in RPA using a JE-specific 32P-labeled probe (lane P). Transfection
reagents used are indicated.
FIG. 5. Virus growth characteristics. Samples of media were col-
lected at indicated intervals post-transfection (a) or post-infection (b)
and virus titers in the media were determined by plaque assays. (a)
BHK cells (2 3 105) were transfected with 1 mg of plasmids and
SuperFect (Qiagen). Series 1, pCMVp/eJE(i356i2217)BGHTT; series 2,
pCMVp/eJE(i356i2217); series 3, pCMVp/eJE(i356)BGHTT. (b) BHK cells
(2 3 105) were infected with 100 pfu of the parent virus or with the virus
recovered from pCMVp/eJE(i356i2217)BGHTT.
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276 YAMSHCHIKOV, MISHIN, AND COMINELLIWe also determined specific infectivities of DNA con-
structs by transfecting serially diluted plasmids and ob-
serving plaque formation after incubation of transfected
cells under semisolid overlays. For the same construct,
specific infectivities varied substantially depending on
transfection reagents used (see also Fig. 4b). The high-
est values observed with SuperFect (Qiagen) were in the
range 0.1–1 3 106 pfu/mg of plasmid DNA, with no sig-
nificant differences between plasmids containing one or
two introns. Interestingly, we also did not observe a
substantial divergence between plasmids pCMVp/
eJE(i356i2217)BGHTT and pCMVp/eJE(i356i2217), al-
though the former had the defined termination and poly-
adenylation signal. In the latter, the termination and poly-
adenylation signal(s) probably was provided by the
vector. We did not investigate this question in detail.
Thus, all full-genome JE cDNA constructs controlled by
the eukaryotic promoter initiated the virus infectious cy-
cle directly upon transfection of DNA into cells. To our
knowledge, this is the first report describing the design
of a flavivirus infectious DNA construct.
Characterization of the recovered virus
As evidenced in Fig. 6a, virus recovered from pCMVp/
eJE(i356i2217)BGHTT produced plaques similar to those
of the parent virus. Accordingly, both viruses produced
identical growth curves (Fig. 5b), thus corroborating re-
sults of plaque assays. A possibility of cross-contamina-
tion was excluded since the Ecl136 II site at pos. 354 was
present in the genome of the recovered virus (Fig. 6b,
lane 4), compared to the parent virus (lane 2). This was
FIG. 6. Characterization of the recovered virus. (a) BHK cells (2 3 105)
ere infected with indicated viruses and incubated under semisolid
verlay for 5 days. Plaques were visualized by crystal violet staining. (b)
T-PCR analysis of total RNA isolated from cells 72 h after infection
ith the parent or the recovered viruses with primers flanking pos. 356
f intron insertion. Lanes 1, 2—parent virus; lanes 3, 4—recovered
irus; lanes 1, 3—RT-PCR product; lanes 2, 4—RT-PCR product di-
ested with Ecl136 II. Lane M—200-bp DNA ladder. (c) Primer exten-
ion assay with 32P-labeled JE-specific primer. The sequencing ladder
(lanes G, A, T, C) was prepared with the same primer and pCMVp/
e59D39BGHTT; the corresponding sequence of the JE 59-end is given on
the right. Lane 1, recovered virus; lane 2, parent virus; lane 3, uncapped
T7 transcript prepared from pT7JE59.confirmed by sequencing through the region adjacent to
this site.We have further determined whether genomic RNA of
the recovered virus possesses the authentic 59- and
39-ends. Total RNA from cells infected with either of the
viruses was analyzed in comparison with uncapped syn-
thetic RNA prepared with T7 polymerase from pT7JE59.
Reverse transcriptase extension products of a primer
complementary to pos. 80–100 of the JE genome are
shown in Fig. 6c, alongside the DNA sequencing ladder
prepared from pCMVp/e59D39BGHTT using the same
primer. In the T7JE59 construct, the T7 transcription start
is engineered to the beginning of the JE genome; accord-
ingly, the major extension product terminated at the 59-
terminal A (lane 3). Slight infidelity of transcription initi-
ation by T7 RNA polymerase may have accounted for the
minor presence of longer and shorter extension frag-
ments. Major extension products of the same length
were observed for both viruses (lanes 1 and 2). Both
were longer by one nucleotide, which likely resulted from
copying the cap structure by reverse transcriptase
(Dubensky et al., 1996). The sequence at the JE RNA
59-end was determined using a RLM-RACE kit (Ambion)
and was found to be identical for both viruses. Sequence
at the 39-end of JE RNA was determined using the
adapted RACE-PAT assay (Salles et al., 1999) after poly-
adenylation of total RNA from infected cells in the pres-
ence of poly(A) polymerase, and was also found to be
identical for both viruses. Finally, two cDNA fragments
covering the entire viral genome were obtained by RT-
PCR of total RNA from cells infected with the recovered
virus. These fragments were purified and completely
sequenced. No differences, except for the two silent
mutations introduced to create the Ecl136 II site at pos.
354, were found, when compared to the genome se-
quence of the parent virus.
The above data confirmed that the virus recovered
from pCMVp/eJE(i356i2217)BGHTT was identical to the
parent virus, in both phenotype and genotype (except for
the two mutations).
DISCUSSION
Despite benefits associated with use of infectious
DNA constructs, only a few successful applications of
this methodology have been reported for a limited set of
animal (1)RNA viruses (Semler et al., 1984; Herweijer et
al., 1995; Dubensky et al., 1996; Beard et al., 1999).
Characteristically, these examples are either nonenvel-
oped viruses or enveloped viruses containing genes of
nonstructural proteins in the beginning of their genomes.
In either case, genome regions proximal to a eukaryotic
promoter do not encode extensive stretches of hydro-
phobic amino acids, and this perhaps may account for
the stability of reported infectious plasmids during prop-
agation in E. coli. In contrast, representatives of the
Flaviviridae family encode structural proteins, most of
which are membrane-associated, in the beginning of
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277DESIGN OF (1)RNA VIRUS INFECTIOUS CLONEStheir genomes. In this case, spurious transcription from
eukaryotic promoters likely results in synthesis of prod-
ucts toxic for E. coli, which may serve as a major desta-
ilizing factor preventing design of such plasmids. In-
eed, the only flavivirus DNA/RNA layered construct re-
orted to date was designed for a replicon of Kunjin virus
Varnavski et al., 2000), which did not include the genome
region coding for its structural proteins. In addition, as
discussed below, the presence of promoter-like se-
quences inside the viral genome or foreign gene cas-
settes may further jeopardize the stability of recombinant
plasmids in E. coli. To circumvent these problems, we
have attempted to take advantage of the major difference
in mRNA formation between prokaryotes and eukaryotes
by using eukaryotic RNA processing mechanisms as the
essential part of the clone stabilization strategy. This
approach was conceived from the observation that a
single nonsense mutation, presumably preventing syn-
thesis of toxic products, often was sufficient to stabilize
the entire construct. Hence, temporary ablation of such
deleterious expression at the level of translation by in-
terrupting the ORF, with help of an intron containing stop
codon(s), would be beneficial during propagation of re-
combinant plasmids in E. coli. The intron would effec-
tively block synthesis of toxic products in the bacterial
host, even if spurious transcription resulted in formation
of mRNA. Nuclear transcription in eukaryotic cells, ac-
companied by splicing of the primary transcripts, would
lead to precise excision of the intron and restoration of
the original ORF. For virus infectious clones and viral
replicon-based expression vectors, subsequent export of
mRNA to cytoplasm and its translation would result in
synthesis of viral proteins, which may initiate the viral
infectious cycle or replication of vector RNA. Successful
implementation of this approach enabled us to design a
flavivirus infectious DNA construct for the first time. We
believe that this approach in general can be applied to
the design of infectious DNA for other viruses and DNA-
based viral replicon expression vectors, although its im-
plementation will be unique for each viral genome.
Translational blocks may be introduced where sponta-
neous stabilizing mutations arise during maintenance of
instable constructs in E. coli. In pT7JE/Asp, stabilizing
mutations often appeared upstream from the E stop-
transfer/NS1 signal sequence, despite the presence of
two comparable hydrophobic domains upstream from
this region. The T7 promoter itself is not transcriptionally
active in E. coli; perhaps, spurious transcription was
initiated from a prokaryotic promoter-like sequence lo-
cated somewhere in the E gene. Indeed, complete sta-
bilization of the T7JE/Asp clone was achieved by the
single intron insertion at i2217, probably because it pre-
vented expression of the problem genome region at the
level of translation. Replacement of the T7 promoter with
CMVp/e, transcriptional activity of which in E. coli has
been reported (Davis and Huang, 1988; Antonucci et al.,1989), resulted in destabilization of the JE59(i2217) cas-
sette. Accordingly, the stabilizing mutation now has been
found upstream from the prM signal sequence, and in-
sertion of a second copy of the intron upstream from this
region has resulted in complete stabilization of the con-
struct. Removal of the intron at i2217 again destabilized
the plasmid, suggesting initiation of spurious transcrip-
tion from an upstream element. The infectious clone for
YF virus also was unstable under control of the bacte-
riophage promoter (Rice et al., 1989), suggesting the
existence of an internal promoter-like sequence(s) in the
YF genome. For a recently reported coronavirus infec-
tious clone (Almazan et al., 2000), destabilizing se-
quences found inside the virus genome might also indi-
cate the existence of such elements. It would be inter-
esting to test whether YF and coronavirus infectious
clones can be substantially stabilized by inserting tem-
porary translational blocks upstream from the problem
genome regions.
A possible problem for implementation of the pro-
posed approach is associated with potential existence of
cryptic splice sites in viral RNA genomes (Shiu et al.,
1997). Although we found several such potential sites in
the JE genome, this did not appear to have a substantial
impact on the functional properties of designed infec-
tious DNA constructs. We were unable to detect alterna-
tive splicing for the construct containing two introns.
However, this may be explained by a low sensitivity of
the protocols used. On the other hand, no significant
difference was found in the specific infectivities of con-
structs containing one intron and two introns, and both
plasmids produced virus with identical accumulation
rates. Assuming that roughly 1 mg equals 1 pmol for a
1500-bp DNA fragment, and assuming that theoretically 1
molecule of infectious DNA per cell is enough to initiate
the infectious cycle, the specific infectivity of 106 pfu/mg
that we have observed is about four orders of magnitude
less than the theoretically possible value for a 16,000-bp
plasmid. While protocols affording higher transfection
efficiencies may increase the specific infectivity of the
constructs, we cannot exclude the possibility that alter-
native splicing may have affected the specific infectivity.
Although no deleterious splicing was detected even with
the large coronavirus infectious DNA clone (Almazan et
al., 2000), this may not be the case for other virus con-
structs, and certain efforts such as mutagenesis might
be required to alleviate the problem.
The current thinking is that the fidelity of the transcript
59- and 39-end formation influences the specific infectiv-
ity of synthetic RNA. We cannot exclude the possibility
that a higher specific infectivity may be obtained if the
39-end is made authentic to genome RNA, although it is
unclear how that could be implemented without affecting
RNA processing and transport. For other viruses, which
require more precise formation of the RNA ends, this
could create another potential problem. A possible rem-
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278 YAMSHCHIKOV, MISHIN, AND COMINELLIedy may be to use a self-cleaved ribozyme in anticipation
that some transcripts would be polyadenylated and ex-
ported before such self-cleavage takes place, with for-
mation of the authentic 39-end occurring in the cytoplasm
(Varnavski et al., 2000).
We believe that the proposed approach may be useful
for further development of infectious DNA methodology.
A stable infectious DNA molecular clone easily propa-
gated in E. coli offers a simple, convenient, and cost-
effective way of maintaining virus and vaccine deposito-
ries (Kohara et al., 1986), thus alleviating to a significant
extent the problem of genetic drift associated with prop-
agation of vaccine and viral stocks in eukaryotic hosts.
With the advent and rapid development of DNA immuni-
zation (Donnelly et al., 1997), the infectious DNA ap-
proach may acquire new meaning that opens new pos-
sibilities both in the current immunization practice and in
vaccine design. Use of infectious DNA clones derived
from existing (1)RNA virus vaccines for immunization
directly (Ward et al., 1997) may help underdeveloped
countries to pursue more extensive immunization cam-
paigns, since vaccines in the infectious DNA form may
be less dependent on maintenance of the cold chain.
Furthermore, full genome DNA constructs controlled by
eukaryotic promoters together with high transfection ef-
ficiency protocols offer the unique possibility of dissoci-
ating synthesis and processing of viral proteins from
replication of viral RNA. Studies that seek to evaluate the
feasibility of this methodology for the design of new
vaccine candidates based on pseudolethal viral mutants
are currently in progress.
MATERIALS AND METHODS
Cells and viruses
BHK (Bredenbeek et al., 1993) and Vero (ATCC CRL-
1586) cells were maintained at 37°C in humidified atmo-
sphere containing 5% CO2 in DMEM (GIBCO-BRL) con-
aining 5% FCS (Hyclone) and 13 antibiotic–antimycotic
ixture (GIBCO-BRL). Stocks of both the wild-type JE
irus (strain JaOArS982 (Sumiyoshi et al., 1987)) and the
E viruses recovered from infectious clones were pre-
ared on Vero cells. All work with infectious material was
erformed under Biosafety Level 3 containment.
lasmid construction
DNA was manipulated using standard procedures
Sambrook et al., 1989) with commercially available en-
ymes. Throughout the study, NIH Guidelines for Re-
earch involving Recombinant DNA Molecules were fol-
owed. E. coli strain HB101 (F2D(gpt-proA)62 leuB6
upE44 ara-14 galK2 lacY1 D(mcrC-mrr) rpsL20(Strr) xyl-5
tl-1 recA13) was used for cloning and maintenance of
ecombinant constructs. Sequencing of cDNA fragments
nd plasmids was done using an ABI 310 Genetic Ana-
yzer (PE Applied Biosystems, Foster City, CA).The pT7JE59 plasmid containing the 59-half of JE (strain
aOArS982) genome cDNA, pos. 1–5576, under control of
he T7 promoter was derived from pM343 (Sumiyoshi et
l., 1992) by replacement of the HpaI–SacI (pos. 1814–
215) fragment containing a single nucleotide deletion at
os. 2023 with the similar fragment amplified by RT-PCR
rom JE genomic RNA. The pJE39/Asp plasmid containing
he 39-half of JE genome cDNA, pos. 5576–10960, was
erived from pH756 (Sumiyoshi et al., 1992) by inverting
he JE fragment relative to the origin of replication in
BR322 with simultaneous replacement of the SalI site at
he JE 39-end with the Asp718 (abbreviated here to Asp;
lso created in pBR322 in place of ClaI) by linker addi-
ion. The pT7JE/Asp infectious clone was assembled
rom pT7JE59 and pJE39/Asp between SalI and Asp718
ites in pBR322 (Fig. 1a). The CMVp/e-59JE junction (Fig.
b) was created by overlapping PCR from pCIneo (pos.
–744, Promega, Madison, WI) with addition of a SalI site
nd from JE cDNA (pos. 1–943), and was used as a
alI–MluI fragment. The intron was amplified from
CIneo (pos. 890–1022) and inserted by blunt-end liga-
ion into Ecl136 II sites at pos. 354 and pos. 2215 (Fig. 1a).
he former was created by PCR-directed silent mutagen-
sis (A3G and T3C, pos. 356 and 358). The PmeI–MluI
ragment of JE cDNA, which included both copies of the
ntron, replaced the corresponding fragment in pT7JE59.
he pCMVp/eJE59(i356i2217) and pCMVp/eJE59(i356)
lasmids were obtained after subsequent exchange of
he SalI–MluI fragments. The full genome JE constructs
CMVp/eJE(i356i2217) and pCMVp/eJE(i356) were cre-
ted by addition of the 39-half of JE cDNA from pJE39/Asp.
264-bp Ecl136 II–PvuII BGHTT fragment from pcDNA3
pos. 1021–1286, Invitrogen, San Diego, CA) was inserted
nto the filled-in Asp718 site at the end of the JE cassette
n both plasmids producing pCMVp/eJE(i356i2217)BGHTT
nd pCMVp/eJE(i356)BGHTT.
For mapping of the 59- and 39-ends of primary tran-
cripts, pCMVp/e59D39BGHTT was created by deleting a
iddle MluI fragment (pos. 929–8162) of the JE genome.
or the ribonuclease protection assays (RPA), a JE cDNA
ragment (pos. 1–175) was subcloned into pGEM3 (Pro-
ega) to prepare the negative strand probe by run-off
ranscription of the linearized template from the T7 pro-
oter.
solation and analysis of RNA
Total RNA was isolated with the RNeasy Mini Kit (Qia-
en, Chatsworth, CA) and DNase treatment according to
he manufacturer. RNA was quantified assuming that 1
260 equals 40 mg/ml. Prior to RT-PCR assays, RNA was
again treated with RNase-free DNase (Sigma, St. Louis,
MO) in the presence of 1 mM MgCl2. DNase was inac-
tivated at 65°C (10 min). The RT-PCR kit (Promega) and
the RPA II kit (Ambion, Austin, TX) were used for the
corresponding assays. The JE-specific RNA probe for
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279DESIGN OF (1)RNA VIRUS INFECTIOUS CLONESRPA was prepared using [32P]UTP (800 Ci/mmol; NEN,
oston, MA) and the MAXIscript kit (Ambion) according
o the manufacturer. Two micrograms of total RNA per
ample was used for RT-PCR and RPA.
The sequence at the 59-end of the primary transcripts
nd JE viral RNA was determined using the RLM-RACE
it (Ambion) according to the manufacturer’s protocol.
riefly, 5 mg of total RNA from cells transfected with
pCMVp/e59D39BGHTT or virus-infected cells was de-
phosphorylated with alkaline phosphatase, treated with
tobacco acid pyrophosphatase to remove the 59-cap
structure, and then ligated to a supplied RNA linker in the
presence of RNA ligase. Following nested RT-PCR using
two sets of RNA linker-specific and JE-specific primers, a
gel-purified fragment was sequenced.
The 39-end sequences of the primary transcripts and
of JE viral RNA were determined using an adapted RACE-
PAT assay (Salles et al., 1999). For transcripts, 3–5 mg of
otal RNA from transfected cells was used; for viral RNA,
he same amount of total RNA from infected cells prior to
he assay was polyadenylated in the presence of poly(A)
olymerase according to the manufacturer (Epicentre
echnologies, Madison, WI). Following nested RT-PCR,
el-purified fragments were sequenced.
Analysis of primary transcript splicing and character-
zation of viral RNA were done by RT-PCR using direct
rimers corresponding to pos. 1–25 and 1966–1987, and
everse primers complementary to pos. 919–943 and
306–2330 of the JE genome.
etection and analysis of viral proteins
Indirect immunofluorescence assays were used for
etection of JE antigens in transfected cells. Cell mono-
ayers grown on glass coverslips were fixed by 5% acetic
cid in methanol at 220°C for 20 min, washed with
-PBS (GIBCO-BRL, Gaithersburg, MD), and incubated
ith 1:100 dilution of JE immune mouse ascites fluid (AF,
TCC VR-1259 AF) in D-PBS for 1 h at ambient temper-
ture, followed by fluorescein-conjugated goat anti-
ouse IgG (GIBCO-BRL) at 1:100 dilution in D-PBS. Im-
unoprecipitation of JE proteins from transfected cells
sing AF and electrophoretic analysis of samples were
arried out as described earlier (Yamshchikov and Com-
ans, 1993).
ransfection, metabolic labeling, and virus assays
Transfection of BHK with plasmid constructs was per-
ormed using SuperFect (Qiagen) and Fugene6 (Roche,
ndianapolis, IN) reagents according to the manufactur-
rs. Cells (2 3 105) were transfected with 2 mg of DNA for
1–3 h, washed twice with D-PBS, and incubated in the
growth medium for specified time periods. Prior to label-
ing, cells were starved for 1 h in the Met-deficient MEM
35(GIBCO-BRL), labeled for 1 h with 100 mCi of the [ S]-
Labeling Mix (NEN), and then chased in the growthmedium for 3 h before harvesting as described earlier
(Yamshchikov and Compans, 1993).
To determine virus growth characteristics, 2 3 105
BHK cells in six-well plates were either transfected with
1 mg of infectious plasmids or infected with 100 pfu of
iruses. Following 3-h transfection or 1-h virus adsorp-
ion periods, cells were washed with D-PBS and incu-
ated in the growth medium for 4 days. At indicated
ntervals, samples of media were collected and frozen.
iters of virus samples were determined by plaque assay
f serial 10-fold virus dilutions on BHK cells. Following
-h adsorption, virus inoculum was removed; cell mono-
ayers were washed once with D-PBS and overlaid with
MEM containing 2% FCS and 1% methylcellulose
Sigma). Cells were incubated for 3–5 days, the overlay
as removed, and plaques were visualized by staining
ith 1% crystal violet (Sigma) in 70% methyl alcohol. The
ame procedure was used for plaque assays following
-h transfection with serial 10-fold dilutions of plasmids
n the presence of 1 mg of carrier DNA (pBR322).
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